RiboMed Biotechnologies, Inc., a San Diego area biomarker discovery and diagnostics company, announced today the receipt of a $150,000 Phase I contract from the National Cancer Institute (NCI) to develop bisulfite-free, DNA methylation based diagnostic assays for prostate, bladder, kidney and testicular cancer.
Tests will utilize RiboMed’s proprietary signal amplification technology, Abscription®. RiboMed has received four new U.S. patents related to Abscription® in the last year for disease- associated biomarker detection.
“This contract allows us to continue work that we started last year with NCI funding through its Innovative Molecular Analysis Technologies Program (IMAT),” said RiboMed CEO Michelle Hanna.
“RiboMed’s abscription-based detection tests are extremely sensitive and specific while still being affordable. They are ideally suited for non-invasive diagnostic and prognostic tests based on disease and drug associated biomarkers found in bodily fluids.”
About RiboMed Biotechnologies, Inc.
RiboMed Biotechnologies is performing leading edge research and development in the area of non-invasive tests and companion diagnostics for the early detection of for cancers and other diseases.
An Arizona corporation with research facilities in Carlsbad, California, RiboMed provides its customers, including leading Universities, Government Research Agencies and corporate partners with DNA Methylation Services, pre-packaged bi-sulfide free methylation test kits, and individual component compounds including a selection of Nucleotide Analogs and other products and supplies.RiboMed® products include:
· MethylMagnet® mCpG DNA Isolation Kits for researchers looking for an alternative to bisulfite conversion.
· MethylMagnet® mCpG Island Primer Kits for researchers who prefer a kitted solution with validated primers,
· MethylMagnet® Custom Assays for researchers that have a specific locus of interest
For more company information and a full product catalog, visit us on line at www.RiboMed.com.RiboMed®, Abscription®, and MethylMagnet® are registered trademarks of RiboMed Biotechnologies, Inc.
Michelle M. Hanna, PhD
CEO & Scientific Director
RiboMed Biotechnologies, Inc.
1989 Palomar Oaks Way, Suite B
Carlsbad, CA 92011
Safe Harbor Statement This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and RiboMed’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. RiboMed Biotechnologies, Inc. undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.